What does this research mean for the field?

Dexmedetomidine continuous infusion is a feasible bridge sedation therapy for severely agitated adolescents in the emergency department, although nearly half of patients may still require additional sedation. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate the feasibility and safety of dexmedetomidine continuous infusion as bridge sedation for severely agitated adolescents awaiting psychiatric evaluation and disposition in the emergency department.

September 3, 2026Annals of Emergency MedicineOpen Access

Dexmedetomidine Continuous Infusion to Maintain Sedation in Severely Agitated Adolescents in the Emergency Department

View Full Paper

Ask AI

Bookmark

Authors

GCGiorgio Cozzi AZAlessandro Zago AMAlberto J. Di Mascio

Discussion

Member takes

Overview

Retrospective study reveals dexmedetomidine infusion provides bridge sedation in agitated adolescents, indicating its feasibility while awaiting psychiatric disposition.

Key Points

To evaluate the feasibility and safety of dexmedetomidine continuous infusion as bridge sedation for severely agitated adolescents awaiting psychiatric evaluation and disposition in the emergency department.
Retrospective review of adolescents aged 12 to 17 years (N=20) receiving dexmedetomidine infusion for severe agitation in an emergency department over a 16-month period.
Abstracted demographics, sedative use, psychiatric therapies, adverse events, and hospital disposition, with a primary outcome of requiring additional sedation during the infusion.
Patients received dexmedetomidine for a median of 21 hours with a median maximum dose of 1.6 mcg/kg per hour, and 45% (9/20; 95% CI, 26% to 66%) required supplemental sedation.
Adverse outcomes included one patient with transient desaturation resolved by airway repositioning and oxygen, while five patients required transfer to the pediatric ICU for multiple sedatives.

Cite This Study

Cozzi et al. (2026) studied this question.

synapsesocial.com/papers/6a993600636c6408cfa7ebaa https://doi.org/10.1016/j.annemergmed.2026.07.004

View Full Paper

Ask AI

Bookmark

September 3, 2026Annals of Emergency MedicineOpen Access

Dexmedetomidine Continuous Infusion to Maintain Sedation in Severely Agitated Adolescents in the Emergency Department

View Full Paper

Ask AI

Bookmark

Authors

GCGiorgio Cozzi AZAlessandro Zago AMAlberto J. Di Mascio

Discussion

Member takes

Overview

Retrospective study reveals dexmedetomidine infusion provides bridge sedation in agitated adolescents, indicating its feasibility while awaiting psychiatric disposition.

Key Points

To evaluate the feasibility and safety of dexmedetomidine continuous infusion as bridge sedation for severely agitated adolescents awaiting psychiatric evaluation and disposition in the emergency department.
Retrospective review of adolescents aged 12 to 17 years (N=20) receiving dexmedetomidine infusion for severe agitation in an emergency department over a 16-month period.
Abstracted demographics, sedative use, psychiatric therapies, adverse events, and hospital disposition, with a primary outcome of requiring additional sedation during the infusion.
Patients received dexmedetomidine for a median of 21 hours with a median maximum dose of 1.6 mcg/kg per hour, and 45% (9/20; 95% CI, 26% to 66%) required supplemental sedation.
Adverse outcomes included one patient with transient desaturation resolved by airway repositioning and oxygen, while five patients required transfer to the pediatric ICU for multiple sedatives.

Cite This Study

Cozzi et al. (2026) studied this question.

synapsesocial.com/papers/6a993600636c6408cfa7ebaa https://doi.org/10.1016/j.annemergmed.2026.07.004

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark